## BDX: Becton, Dickinson and Company - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.7% below STRENGTH zone (3.0-6.0%); PEG 1.03 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-4.3% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($186.50)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 1, Bearish: 2)

**1. Safety Syringes Market Is Going to Boom |• BD (Becton Dickinson and Company) • Covidien (Medtronic)**
- Source: openPR.com | 20251216T090732 | Bullish | Relevance: 100%
- Worldwide Market Reports (WMR) predicts substantial growth for the "Safety Syringes Market" in the coming years, offering a comprehensive analysis of market dynamics, drivers, and regional insights. The report includes an enhanced 2032 Edition with updated data, competitive landscape analysis of key players like BD and Medtronic, and outlines segmental highlights by types and applications. It emphasizes robust research methodology and aims to provide actionable intelligence for business growth and investment decisions.

**2. Becton, Dickinson and Company (NYSE:BDX) EVP Sells $123,302.87 in Stock**
- Source: MarketBeat | 20251218T025311 | Neutral | Relevance: 100%
- Becton, Dickinson and Company (NYSE:BDX) EVP Michael David Garrison sold 629 shares of the company's stock for a total of $123,302.87 on December 17th, reducing his stake by 4.58%. The company recently increased its quarterly dividend to $1.05 per share, yielding approximately 2.1%. Analysts currently have a "Hold" consensus rating on BDX with an average target price of $205.64.

**3. Westwood Holdings Group Inc. Decreases Holdings in Becton, Dickinson and Company $BDX**
- Source: MarketBeat | 20251216T134115 | Neutral | Relevance: 100%
- Westwood Holdings Group Inc. significantly reduced its stake in Becton, Dickinson and Company (NYSE:BDX) by 51.5% in the second quarter, selling 41,701 shares to hold 39,218 shares valued at approximately $6.76 million. Despite this, Becton, Dickinson and Company increased its quarterly dividend to $1.05 per share, offering a 2.1% yield. The company currently holds a consensus "Hold" rating from Wall Street analysts with an average price target of $204.91.

**4. Cardinal Capital Management Inc. Grows Holdings in Becton, Dickinson and Company $BDX**
- Source: MarketBeat | 20251216T104249 | Neutral | Relevance: 100%
- Cardinal Capital Management Inc. increased its stake in Becton, Dickinson and Company by 4.4% to 143,928 shares, valued at approximately $26.94 million. Institutional ownership of BDX is high at 86.97%, with major firms also increasing their positions. Analysts have a mixed view with a "Hold" consensus rating and an average target price of $204.91, while the company recently raised its quarterly dividend to $1.05 per share.

**5. Northside Capital Management LLC Has $9.92 Million Position in Becton, Dickinson and Company $BDX**
- Source: MarketBeat | 20251217T130447 | Somewhat-Bullish | Relevance: 99%
- Northside Capital Management LLC significantly increased its stake in Becton, Dickinson and Company (NYSE:BDX) by 15% in Q3, now holding 53,012 shares valued at $9.92 million. Becton, Dickinson recently raised its quarterly dividend to $1.05 per share, resulting in an annualized dividend of $4.20 and a 2.1% yield. The company's stock trades near $196.42 with a PE ratio of approximately 33.7, and analysts generally rate it as a "Hold" with an average price target of $204.91.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-17 | RBC Capital | $210 | $202 | +4% |
| 2025-12-02 | Morgan Stanley | $210 | $197 | +7% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-17 | RBC Capital | main | Sector Perform |
| 2025-12-02 | Morgan Stanley | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 13 ($0.04M) |
| Sells | 6 ($0.07M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 10 / 0 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (+0.5%)
- Blackrock Inc.: 9.7% (+1.7%)
- T. Rowe Price Invest: 5.7% (+0.3%)
- State Street Corpora: 4.9% (+3.4%)
- JPMORGAN CHASE & CO: 3.7% (+132.7%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-4.3% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.03 suggests fair value with growth premium. Balance sheet: $2.7B free cash flow. Analyst sentiment positive (2 raises, avg +5%). Institutional flow bullish (10 buying vs 0 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $55.8B |
| Beta | 0.28 |
| 52W Range | $162.29 - $251.99 |
| Short Interest | 1.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.03 |
| Forward P/E | 12.3 |
| Current P/E | 13.0 |
| YoY Growth | 6.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 5.0% to 0.7% (-4.3% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.3pp (needs >3.0% for momentum thesis). MRS_5 (-1.4%) diverging from MRS_10 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 53. OFD pattern: -SUH (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.72% (CS: 45) | Neutral |
| RSI_14 | 52.9 | Neutral |
| MACD Histogram | -0.06 | Bearish |
| vs SMA20 | 1.002x | Above |
| vs SMA50 | 1.029x | Above |
| vs SMA200 | 1.026x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $194.72
- **Stop Loss:** $186.50 (4.2% risk)
- **Target:** $202.94 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 115
- **Position Value:** $22,392.80
- **Portfolio %:** 22.39%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with cautious positioning ahead of CPI data. VIX at moderate 16.87 with positive yield curve suggesting stable growth, but narrow breadth at 51.8% indicates selective participation. Banking sector optimism and corporate resilience provide support, though AI volatility creates pockets of uncertainty.*

### Earnings

**Next:** 2026-02-09 (Est: $2.81)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.91 | $3.96 | +1.1% |
| 2025Q2 | $3.40 | $3.68 | +8.2% |
| 2025Q1 | $3.28 | $3.35 | +2.1% |
| 2024Q4 | $2.99 | $3.43 | +14.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*